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Is It Lawful and Ethical to Prioritize Racial Minorities
for COVID-19 Vaccines?
Coronavirus disease 2019 (COVID-19) has dispropor-
tionately affected racial minorities in the United States re-
sulting in higher rates of infection, hospitalization, and
death. With a limited supply after the initial approval of a
safeandeffectivevaccine,difficult legalandethicalchoices
will have to be made on priority access for individuals.
The National Academies of Sciences, Engineering,
and Medicine (NASEM) has recommended prioritiza-
tion of racial minorities who are “worse off” socioeco-
nomically and epidemiologically.1 The World Health Or-
ganization (WHO) similarly cautioned that “colorblind”
allocation frameworks could perpetuate or exacerbate
existing injustices. Both NASEM and WHO urge policy
makers to allocate vaccines in ways that reduce unjust
health disparities.2 The ethics and legality of race-
based policies in the United States have been fraught
with controversy.3 This Viewpoint considers how
COVID-19 vaccine priority allocations could be imple-
mented ethically and legally.
COVID-19 and Communities of Color
Compared with the rate of COVID-19–related deaths
among non-Hispanic White individuals (mortality rate,
38/100 000) and adjusting for age, the mortality rate
relative to population size is 3.4-fold higher among Black
individuals (mortality rate, 131/100 000), 3.3-fold higher
among Indigenous and Latino communities (mortality
rate for both, 125/100 000), 2.9-fold higher among Pa-
cific Islander individuals (mortality rate, 111/100 000),
and 1.3 higher among Asian populations (mortality rate,
50/100 000).4 These elevated death rates are unlikely
to be explained by biological differences1 but more likely
are influenced by social determinants of health, includ-
ing economic privation and systemic bias. To avoid fur-
ther compounding these disparities, the NASEM ex-
pressly includes “mitigation of health inequities” as 1 of
the 3 foundational principles of its framework.1
The Ethical Case for Considering Race
The ethical justification for prioritizing economically
worse-off racial minorities rests on epidemiological, eco-
nomic, and social justice grounds.1,2,5 Economically,
worse-off groups are more dependent on regular in-
come with little or no retirement or other savings, and
less able to work remotely. Epidemiologically, worse-
off groups are more likely to live with multiple genera-
tions in close proximity and are typically less able to
physically distance at home, at work, and while com-
muting to work (if they are employed), and therefore at
greater risk of contracting and spreading severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2).
Social justice rationales are based on the disparate
outcomes that worse-off racial minorities, especially
Black persons in the United States, have experienced in
terms of higher rates of COVID-19–related unemploy-
ment, housing evictions, and hospitalizations. Ignoring
these effects in allocating vaccines could exacerbate
these differences, with an influence lasting likely far be-
yond the end of the pandemic.5
NASEM Framework
The Centers for Disease Control and Prevention (CDC)
and the National Institutes of Health (NIH) commis-
sioned the NASEM to provide recommendations to the
CDC’s Advisory Committee on Immunization Practices
(ACIP). ACIP will issue national guidance, implemented
by the states. ACIP has indicated it would be guided by
the NASEM framework, particularly the way in which mi-
norities will be prioritized.
The NASEM framework allocates vaccines in 4
sequential phases, with distinct priority populations.
Within each population group, vaccine access would be
prioritized for geographic areas identified as vulnerable
through a statistical measure called the Social Vulner-
ability Index (SVI). The SVI (developed for public health
emergencies such as hurricanes or earthquakes) identi-
fies geographic areas of vulnerability based on 15 cen-
sus variables “most linked to the disproportionate
impact of COVID-19 on people of color and other vul-
nerable populations.”1 The CDC advises state-level plan-
ners to draw on the NASEM and the ACIP frameworks,
instructing planners to begin identifying “critical popu-
lations” including “people from racial and ethnic minor-
ity groups.”6 Race, therefore, could be among the
explicit factors that health professionals will use to allo-
cate scarce COVID-19 vaccines.
Are Race-Based Allocation Criteria Lawful?
The US Supreme Court uses a demanding legal stan-
dard in reviewing race-based classifications. There is no
direct precedent in which courts have considered race
in allocating scarce health care resources. The closest par-
allels are found in rulings on school access and univer-
sity admissions. The critical question is whether govern-
ment is permitted to consider race when seeking to
ameliorate the effects of past and current discrimina-
tion. Often called “reverse discrimination,” the policy de-
liberately favors people of color.
In a series of cases, the court has vacillated as to
whether race can be an express criterion for achieving
greater equity and diversity. In striking down public
school integration plans that explicitly included a stu-
dent’s race, Chief Justice Roberts said, “The way to stop
discrimination on the basis of race is to stop discrimi-
nating on the basis of race” (Parents Involved in Com-
munity Schools v Seattle School District No. 1, 551 US 701
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[2007]). Yet the court has permitted race to be one of multiple fac-
tors in ensuring diversity in universities.7
The court has increasingly moved toward limiting the explicit con-
sideration of race, requiring policies categorizing individuals by race
to meet a “strict scrutiny” standard. Under strict scrutiny, race-based
policies must be narrowly tailored to achieve a compelling govern-
mental interest. Even if the court were to rule that promoting equity
is a compelling state interest, it would still require government, wher-
ever possible, to use means other than race to achieve equitable out-
comes. Likewise, the future of race-based discrimination to remedy
past and future disadvantage remains uncertain. The consideration
of race in COVID-19 vaccine allocation could be a potentially attrac-
tive test case for the court given its changing composition.7
Strict judicial scrutiny would not permit 2 vaccine priority strate-
gies. First, a health care worker could not give priority to vaccinating
persons from minority groups, for instance, by skipping White people
waiting in line at a health care facility. Second, public health agencies
couldnotprovidevaccinesexclusively,or inlargershares,togeographic
areas identified by race alone. This would not preclude distribution in
proportion to the population of a vaccine through community health
centers, many of which serve largely urban minority populations.
For strategies that would increase the allocation ratio above that
proportionate to the population, the Supreme Court is likely to uphold
racially neutral vaccine allocation criteria, which are designed to cap-
ture worse-off minorities but not explicitly. A vaccine distribution for-
mula, therefore, could lawfully prioritize populations based on factors
like geography, socioeconomic status, and housing density that would
favor racial minorities de facto, but not explicitly include race.
An example of such a legally permissible approach would be to
use a measure called the Area Deprivation Index (ADI), which is simi-
lar to the SVI, but does not explicitly prioritize on the basis of race.
The ADI reflects the level of socioeconomic deprivation of a geo-
graphic area at the block-group level (600-3000 people) and is as-
sociated with health outcomes.8 The index integrates income, edu-
cation, employment, and housing quality. Although it does not use
race as a variable, the ADI still captures structural disadvantage and
systemic racism because racial minorities are far more likely to be
economically worse off.1,2 The ADI therefore closely tracks racial and
ethnic divides and significantly reduces potential legal concerns that
are associated with using the SVI.
The methodological design of the SVI does not prescribe how its
4 domains (socioeconomic status, household composition, race/
ethnicity and language, and housing and transportation) that are fo-
cused on the census tract level (1200-8000 people) should be
weighed. Current guidance suggests that states will have considerable
discretion in allocations.1,6 Race could therefore account for as little as
one-fifteenth of the overall SVI score (if all variables were considered
equally) or, depending on how the index is configured by a planner,
could become far more prominent, if not determinative.
It is not clear how the Supreme Court would rule on vaccine dis-
tribution based on either the ADI or SVI, but it is likely that the ADI
would be more acceptable because it does not explicitly prioritize
on the basis of race.
Race in the United States
The United States is experiencing an intense reckoning with struc-
tural racism, both because of the disparate health effects of COVID-19
on racial minorities and protests over police violence. Vaccine allo-
cation strategies should not exacerbate racial divisions yet must con-
sider socioeconomic and racial disadvantage. Protected litigation
challenging vaccine allocation plans could disrupt the implementa-
tion of a COVID-19 vaccination plan. Before implementation, ACIP
should model the performance of the SVI against racially neutral stan-
dards such as the ADI, in capturing vulnerable groups while mini-
mizing legal and ethical risks.
Policy makers should also model how many more vaccines
worse-off racial minorities should receive. NASEM suggests that 10%
of all vaccines be reserved for the worst-off SVI quartile in each state.
In addition, states should make “special efforts” to deliver vaccines
to these areas. The more intense the priority that might be given to
racial minorities, the deeper the legal scrutiny will be. In addition, a
seemingly arbitrary arithmetic cutoff point can invite further legal
concern. An equally pragmatic yet more meaningful approach would
consider COVID-19’s effects to date (for example, in terms of deaths
an ADI region incurred) on worse-off racial minorities. Grounding pri-
ority decisions in objective data help justify allocation formulas both
for the general public and for the judiciary.
Public health agencies will have considerable discretion in ra-
tioning scarce COVID-19 vaccines. They could become agents of
change toward improving social and racial justice. Or they can be-
come complicit in allocation strategies that, once again, dispropor-
tionately favor the better-off, White majority. Racially neutral ap-
proaches must be implemented to advance social and racial justice
in the United States.
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